Meningococcal B Investigational Vaccine study - Are you interested?

The Vaccine Trials Group (VTG), Telethon Institute for Child Health Research is currently trialling an investigational vaccine against the most common form of meningococcal disease in Western Australia.

Adolescents and young adults from 10-25 years are still needed for the research project, undertaken by the Vaccine Trials Group at the Telethon Institute for Child Health Research and Princess Margaret Hospital for Children.

Study leader of the Vaccine Trials Group, Dr Peter Richmond, said there is no vaccine available currently to prevent the Meningococcal B strain of the bacteria that accounts for more than 90 per cent of cases in WA.

Meningococcal B can cause meningitis and septicaemia and can progress very quickly with devastating effects. This is the last major cause of meningitis for which there is no vaccine.

The vaccine has previously been studied in clinical trials in young adults, adolescents and toddlers at other Australian sites, including VTG. This is a Phase 3 Clinical trial in adolescents and young adults.

Children between the ages of one month and one year are most at risk from meningococcal disease with a second peak in adolescents, so it's important to ensure that this vaccine is safe and effective in these age groups."

People interested in finding out more can contact the Vaccine Trials Group on Phone: 9340 8542

E-mail: menb@ichr.uwa.edu.au

Website www.ichr.uwa.edu.au/vtg

http://vaccine.childhealthresearch.org.au/clinical-trials/currently-recruiting.aspx

Initial Approval Letter

Parent Information Sheet and Consent Form